A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine

NCT00542893 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Advanced Melanoma

Interventions

DRUG: Genasense® (G3139, oblimersen sodium)
DRUG: Genasense followed by DTIC; then DTIC alone
DRUG: DTIC alone; then Genasense followed by DTIC

Sponsor

Genta Incorporated